天津紅日藥業(yè)股份有限公司成立于1996年，于2000年進(jìn)行股份制改造，2009年10月作為國(guó)內(nèi)首批、天津首家企業(yè)在深證證券交易所創(chuàng)業(yè)板掛牌上市。（股票代碼300026）。
公司自上市后連續(xù)榮登《福布斯》中國(guó)潛力企業(yè)榜、2013年度上市公司金牛獎(jiǎng)百?gòu)?qiáng)綜合榜，榮獲2013年度金牛*佳創(chuàng)業(yè)成長(zhǎng)公司、*具投資價(jià)值上市公司、中國(guó)*具競(jìng)爭(zhēng)力醫(yī)藥上市公司20強(qiáng)、2013中國(guó)創(chuàng)業(yè)板上市公司十佳管理團(tuán)隊(duì)等殊榮。
產(chǎn)品包括：現(xiàn)代中藥血必凈注射液，鹽酸法舒地爾口服制劑以及 抗腫瘤類、免疫調(diào)節(jié)類、血液類、神經(jīng)類、麻醉類、呼吸類、血管類等原料藥和中間體；
Tianjin Chase Sun Pharmaceutical Co. Ltd was founded in 1996 and the joint-stock transformation was completed in 2000. In 2009, Chase Sun pharmaceutical was listed on the Shenzhen Stock Exchange and became the first group of national GEM listed companies, also called as the first of Tianjin. （Stock code: 300026）
In 2013, the company won top 100 comprehensive list of listing Corporation, the best venture growing company in Gold Bull Award 2013, the most investment value listed Company, top 20 of the most competitive pharmaceutical listed Company in China, and the top 10 management team award of 2013 Chinese GEM Listing Corporation.
Products: Xuebijing Injection (Modern Traditonal Chinese Medicine), Fasudil hydrochloride oral preparation; and anti-tumor, immunoregulation, Cardiovascular and cerebrovascular, Anaesthesia API and intermediates;
紅日藥業(yè)技術(shù)轉(zhuǎn)讓中心占地2.5萬(wàn)平米，總投資3億元，擁有多糖、多肽、抗腫瘤等多條合成藥物生產(chǎn)線及大容量注射劑、小容量注射劑、凍干粉針及固體口服制劑生產(chǎn)線，完全按照2010版GMP要求建設(shè)，并擁有完善的檢驗(yàn)分析實(shí)驗(yàn)室，有著完善的生產(chǎn)質(zhì)控體系。技術(shù)轉(zhuǎn)讓中心致力于為客戶提供從化學(xué)原料藥及中間體的臨床前期工藝開(kāi)發(fā)直至工業(yè)化工藝優(yōu)化的服務(wù)。
Technology transfer center of Chase Sun Pharma covers an area of 25,000 square meters with a total investment of 300 million Yuan. Technology transfer center possesses production lines for synthetic drugs, such a polusaccharide, peptides, anti-cancer drugs and production lines for large volume injection, small volume injection, freeze-dried powder and oral solid preparation. Each line is constructed in accordance with the GMP Standard (2010 revision) and has a laboratory for comprehensive testing and analysis with a complete production quality control system. Technology transfer center is committed to providing the customers services of process development of APIs and the intermediates from pre-clinical to the industrialization.
提供如下服務(wù) （產(chǎn)品指原料藥、中間體、精細(xì)化工品）：
Services (Product means API, intermediate and fine chemical)
1： 自產(chǎn)產(chǎn)品的生產(chǎn)銷售 （GMP & Non GMP）；
Own product production, sales;
2： 產(chǎn)品合同定制加工 （GMP & Non GMP）；
Product Contract Manufacturing;
3： 產(chǎn)品研究、開(kāi)發(fā)，成果轉(zhuǎn)化，包括新劑型、新產(chǎn)品中試、放大研究；
Product research and development, achievements transformation including pilot studies and scale-up trials for new preparation and new products;
4： 產(chǎn)品生產(chǎn)工藝條件過(guò)程控制研究；
Studies of controlling the conditions and process of production;
5: 驗(yàn)證技術(shù)成熟型研究；
Validation of the maturity of the technical;
6： 臨床試驗(yàn)用藥和小批量產(chǎn)品生產(chǎn)；
Providing drugs for clinical trials and small batch production;
7： 技術(shù)研究、試驗(yàn)項(xiàng)目和科技項(xiàng)目的咨詢與服務(wù)；
Technology research, pilot project and technology programs advising and services;
8： 藥品注冊(cè)咨詢與服務(wù)；
Drug registration advising and services; |
